Latham & Watkins Named Capital Markets Law Firm of the Year
Chambers USA recognized the firm as a “powerhouse in the capital markets space.”
Nathan Beaton assists clients with regulatory, transactional, litigation, and legislative matters involving the Food and Drug Administration (FDA) and other regulatory authorities with jurisdiction over healthcare and biotechnology. He helps clients in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries navigate all stages of the product life cycle, including:
Mr. Beaton counsels clients on legislation and rulemaking, such as matters relating to the Agriculture Improvement Act of 2018, FDA Reauthorization Act of 2017, 21st Century Cures Act, and Family Smoking Prevention and Tobacco Control Act of 2009. He has been involved extensively in Administrative Procedure Act litigation related to FDA actions and regulatory programs.
His experience extends to matters involving multiple regulatory bodies, including the Drug Enforcement Administration (DEA), US Department of Health and Human Services Office of Inspector General (HHS-OIG), US Department of Agriculture (USDA), and Federal Trade Commission (FTC).
He also regularly advises the regulatory aspects of mergers and acquisitions, equity offerings, financings, and other transactions in the life sciences sector.
A recognized thought leader, Mr. Beaton is a member of the Food and Drug Law Journal’s editorial advisory board and recently co-authored a chapter in A Practical Guide to FDA’s Food and Drug Law and Regulation (7th ed.).
Mr. Beaton’s recent publications and speaking engagements include:
Chambers USA recognized the firm as a “powerhouse in the capital markets space.”
Chambers USA recognized the firm’s Mergers & Acquisitions Practice for “world class expertise when it comes to the most challenging transactions.”